We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$303M
AUM Growth
+$48M
Cap. Flow
+$31.8M
Cap. Flow %
10.49%
Top 10 Hldgs %
45.97%
Holding
88
New
25
Increased
24
Reduced
13
Closed
14

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$13M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$8.63M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.27M
4
CYTK icon
Cytokinetics
CYTK
+$5.46M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.84M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.7M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.34M
3
ESTA icon
Establishment Labs
ESTA
+$5.32M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.05M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 79.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GERN icon
76
PUT
Geron
GERN
$911M
– –
-1,056,500
Closed -$2.56M
IOVA icon
77
Iovance Biotherapeutics
IOVA
$2.23B
– –
-375,000
Closed -$2.4M
MRNA icon
78
PUT
Moderna
MRNA
$21.5B
– –
-30,000
Closed -$5.39M
NVCR icon
79
CALL
NovoCure
NVCR
$2.04B
– –
-25,000
Closed -$1.83M
RCKT icon
80
Rocket Pharmaceuticals
RCKT
$348M
– –
-258,115
Closed -$5.05M
SNDX icon
81
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-100,000
Closed -$2.54M
VKTX icon
82
CALL
Viking Therapeutics
VKTX
$4.04B
– –
-250,000
Closed -$2.35M
VRNA
83
CALL
DELISTED
Verona Pharma
VRNA
– –
-105,000
Closed -$2.74M
MSACW
84
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
– –
-33,333
Closed -$2.93K
1 2 3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Affinity Asset Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Affinity Asset Advisors held 88 positions worth $303M, up 19% from $255M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Affinity Asset Advisors deployed $31.8M of net new capital in Q1 2023, opening 25 new positions and adding to 24 existing holdings. Its largest new stake was Merck: 120,000 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 81% a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $5.7M trimmed.

  • Affinity Asset Advisors's largest Q1 2023 buy was Merck: 120,000 shares worth $12.8M.
  • Affinity Asset Advisors added most to Prometheus Biosciences, Inc. Common Stock in Q1 2023, an estimated $8.63M increase.
  • Affinity Asset Advisors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $5.7M.
  • Affinity Asset Advisors fully exited Rocket Pharmaceuticals in Q1 2023, selling an estimated $5.05M.
  • Affinity Asset Advisors's ten largest holdings make up 46% of its $303M portfolio in Q1 2023.
  • Affinity Asset Advisors opened 25 new positions and closed 14 in Q1 2023.
  • Affinity Asset Advisors's portfolio value rose 19% quarter-over-quarter to $303M.

Based on Affinity Asset Advisors's 13F filing for Q1 2023, filed 15 May 2023.